Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis

• Main Authors: Chuen-Huei Liu (Author), Wen-Hsuan Hou (Author), Pi-Chu Lin (Author), Yi-No Kang (Author), Wei-Ting Liu (Author), Su-Ru Chen (Author)
• Formato: Livro
• Publicado em: Wolters Kluwer Medknow Publications, 2024-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Janus kinase (JAK) inhibitors are promising for inflammatory bowel diseases (IBDs), but their long-term safety, including risks of nonmelanoma skin cancer (NMSC), is uncertain. Objectives: The objective of the study was to conduct a systematic review and meta-analysis to examine the risk...